Form 4: Foundation Fighting Blindness Fund Sells 4M Opus Genetics Shares

Foundation Fighting Blindness Retinal Degeneration Fund reported the sale of 4 million shares of Opus Genetics, Inc. common stock at $2.15 per share.

Summary

• Foundation Fighting Blindness Retinal Degeneration Fund (RDF) and Foundation Fighting Blindness, Inc. (FFB) reported a transaction involving Opus Genetics, Inc. common stock.
• RDF sold 4,000,000 shares of common stock on December 9, 2025.
• The sale price was $2.15 per share.
• Following the transaction, RDF beneficially owns 5,492,171 shares of Opus Genetics, Inc. common stock.
• FFB is the sole member of RDF and may be deemed to beneficially own the securities held by RDF.
• Both entities are considered directors by deputization due to their representatives on the Opus Genetics board.

Sentiment

Score: 3

Explanation: A significant insider, Foundation Fighting Blindness Retinal Degeneration Fund, sold 4,000,000 shares of common stock, which can be interpreted negatively by the market.

Negatives

• A significant shareholder, Foundation Fighting Blindness Retinal Degeneration Fund, sold 4,000,000 shares of common stock.
• The sale occurred at a price of $2.15 per share.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Foundation Fighting Blindness Retinal Degeneration Fund, a 10% owner and deemed director by deputization, sold 4,000,000 shares of Opus Genetics common stock.

Stakeholder Impact

• Shareholders: The sale by a significant shareholder could be perceived negatively, potentially impacting investor confidence and share price.

Key Dates

Recommendation

A significant insider sale of 4,000,000 shares by Foundation Fighting Blindness Retinal Degeneration Fund at $2.15 per share is a notable event. While insider selling can signal a lack of confidence, this single Form 4 filing does not provide sufficient context regarding the reasons for the sale (e.g., portfolio rebalancing, tax planning, or fundamental concerns) to warrant a 'sell' recommendation. Investors should 'hold' and monitor future filings and company performance for additional insights.

Keywords

Opus Genetics, IRD, Foundation Fighting Blindness, Retinal Degeneration Fund, Insider Sale, Form 4, Beneficial Ownership, Common Stock, Equity Transaction